B. Riley Financial Issues Pessimistic Forecast for Enovix (NASDAQ:ENVX) Stock Price

Enovix (NASDAQ:ENVX) had its target price decreased by analysts at B. Riley Financial from $10.00 to $9.00 in a report released on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. B. Riley Financial’s target price suggests a potential upside of 90.27% from the stock’s previous close.

ENVX has been the topic of several other research reports. Craig Hallum lowered their target price on shares of Enovix from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Thursday, May 14th. Weiss Ratings restated a “sell (e+)” rating on shares of Enovix in a research report on Wednesday, July 8th. Benchmark dropped their price target on Enovix from $25.00 to $15.00 and set a “buy” rating for the company in a research note on Thursday, May 14th. JPMorgan Chase & Co. downgraded Enovix from a “neutral” rating to an “underweight” rating in a research note on Wednesday, May 6th. Finally, TD Cowen cut their target price on shares of Enovix from $7.00 to $5.50 and set a “hold” rating for the company in a report on Friday, July 24th. Six equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $12.41.

Enovix Trading Down 2.1%

Shares of ENVX stock opened at $4.73 on Thursday. The company has a current ratio of 10.97, a quick ratio of 10.65 and a debt-to-equity ratio of 2.14. Enovix has a 12-month low of $3.67 and a 12-month high of $14.21. The stock has a market capitalization of $1.03 billion, a P/E ratio of -5.70 and a beta of 2.32. The firm’s 50 day moving average is $5.47 and its 200 day moving average is $5.90.

Enovix (NASDAQ:ENVX) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.02. The firm had revenue of $9.02 million during the quarter, compared to analyst estimates of $8.43 billion. Enovix had a negative net margin of 499.64% and a negative return on equity of 64.28%. The business’s revenue for the quarter was up 20.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.13) EPS. Enovix has set its Q3 2026 guidance at -0.170–0.130 EPS. Research analysts expect that Enovix will post -0.79 earnings per share for the current year.

Hedge Funds Weigh In On Enovix

Several institutional investors have recently made changes to their positions in the company. Private Advisor Group LLC raised its stake in shares of Enovix by 2.7% in the third quarter. Private Advisor Group LLC now owns 46,519 shares of the company’s stock worth $464,000 after purchasing an additional 1,242 shares during the last quarter. Parallel Advisors LLC grew its holdings in Enovix by 51.9% during the third quarter. Parallel Advisors LLC now owns 3,926 shares of the company’s stock worth $39,000 after acquiring an additional 1,342 shares during the period. Equitable Holdings Inc. lifted its holdings in Enovix by 10.9% in the third quarter. Equitable Holdings Inc. now owns 13,700 shares of the company’s stock valued at $137,000 after acquiring an additional 1,342 shares during the period. NewEdge Advisors LLC boosted its position in Enovix by 4.7% in the 1st quarter. NewEdge Advisors LLC now owns 41,460 shares of the company’s stock worth $215,000 after purchasing an additional 1,853 shares in the last quarter. Finally, Mariner LLC grew its stake in shares of Enovix by 3.4% during the 3rd quarter. Mariner LLC now owns 58,343 shares of the company’s stock worth $582,000 after purchasing an additional 1,921 shares during the period. Hedge funds and other institutional investors own 50.92% of the company’s stock.

Trending Headlines about Enovix

Here are the key news stories impacting Enovix this week:

• Positive Sentiment: Enovix reported second-quarter adjusted EPS of $(0.13), better than the consensus estimate of $(0.15), while revenue reached $9.02 million, up 20.8% year over year. The results indicate improving sales momentum and a slightly narrower-than-expected loss. Enovix Q2 earnings report
• Positive Sentiment: Cantor Fitzgerald reaffirmed its Overweight rating and assigned a $25 price target, signaling substantial potential upside based on its expectations for Enovix’s battery technology and growth prospects. Cantor Fitzgerald rating update
• Neutral Sentiment: Management continues to highlight potential demand for Enovix batteries in smartphones, wearables and defense applications. These markets could support long-term growth, but the company still must convert customer interest into meaningful commercial production and revenue. Enovix demand outlook
• Negative Sentiment: Third-quarter revenue guidance of $9 million to $10 million is below the roughly $10.3 million analyst consensus, raising concerns about near-term growth. EPS guidance of $(0.17) to $(0.13) also implies that losses will remain significant. Enovix second-quarter results
• Negative Sentiment: Despite the quarterly beat, Enovix remains deeply unprofitable, with a negative net margin of approximately 500% and negative return on equity. Investors appear focused on the company’s ability to scale production and reduce cash losses rather than on the small EPS beat.

About Enovix

Enovix Corporation (NASDAQ: ENVX) develops and manufactures advanced lithium-ion battery cells with a patented three-dimensional silicon-anode architecture. The company’s core focus is on delivering high energy density, improved safety, and longer cycle life compared to conventional graphite-based cells. Enovix’s technology targets a range of applications, including consumer electronics, wearable devices, electric vehicles and stationary energy storage systems.

Founded in 2011 and headquartered in Fremont, California, Enovix has built pilot production capability and is scaling up manufacturing capacity to meet growing demand.